Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Price Target at $40.88

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has received an average rating of "Moderate Buy" from the eight analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $41.13.

Several brokerages have commented on AKRO. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research report on Monday. Evercore ISI cut their price objective on Akero Therapeutics from $50.00 to $38.00 and set an "outperform" rating on the stock in a research report on Wednesday. UBS Group upped their price objective on Akero Therapeutics from $39.00 to $42.00 and gave the company a "buy" rating in a research report on Tuesday, March 5th. Canaccord Genuity Group cut their price objective on Akero Therapeutics from $59.00 to $56.00 and set a "buy" rating on the stock in a research report on Monday. Finally, Bank of America initiated coverage on Akero Therapeutics in a research report on Monday, April 22nd. They issued a "neutral" rating and a $30.00 price objective on the stock.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $24.38, for a total transaction of $121,900.00. Following the transaction, the chief operating officer now owns 263,306 shares of the company's stock, valued at $6,419,400.28. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, insider Catriona Yale sold 20,646 shares of Akero Therapeutics stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $35.49, for a total transaction of $732,726.54. Following the completion of the sale, the insider now owns 78,415 shares in the company, valued at approximately $2,782,948.35. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Jonathan Young sold 5,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $24.38, for a total value of $121,900.00. Following the completion of the transaction, the chief operating officer now owns 263,306 shares of the company's stock, valued at $6,419,400.28. The disclosure for this sale can be found here. Insiders have sold 105,646 shares of company stock valued at $3,420,627 in the last quarter. Corporate insiders own 9.69% of the company's stock.

Institutional Trading of Akero Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AKRO. Bank of New York Mellon Corp lifted its position in shares of Akero Therapeutics by 225.0% during the third quarter. Bank of New York Mellon Corp now owns 500,245 shares of the company's stock worth $25,302,000 after purchasing an additional 346,317 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Akero Therapeutics by 26.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,878 shares of the company's stock valued at $500,000 after purchasing an additional 2,090 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Akero Therapeutics by 13.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,318 shares of the company's stock valued at $1,533,000 after purchasing an additional 3,499 shares during the period. TD Asset Management Inc increased its stake in shares of Akero Therapeutics by 101.0% during the third quarter. TD Asset Management Inc now owns 126,092 shares of the company's stock valued at $6,378,000 after acquiring an additional 63,346 shares during the period. Finally, New York State Common Retirement Fund increased its stake in shares of Akero Therapeutics by 22.7% during the third quarter. New York State Common Retirement Fund now owns 33,331 shares of the company's stock valued at $1,686,000 after acquiring an additional 6,159 shares during the period.

Akero Therapeutics Price Performance

NASDAQ AKRO traded up $0.77 during trading hours on Wednesday, reaching $21.07. The company's stock had a trading volume of 518,398 shares, compared to its average volume of 1,152,364. The firm's 50-day moving average price is $23.35 and its 200-day moving average price is $21.45. The company has a quick ratio of 29.27, a current ratio of 30.12 and a debt-to-equity ratio of 0.04. Akero Therapeutics has a 1 year low of $11.25 and a 1 year high of $58.38. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -6.76 and a beta of -0.29.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.17). On average, equities research analysts predict that Akero Therapeutics will post -3.93 EPS for the current fiscal year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.